Diagnosis of Intra-amniotic Infection by Proteomic Profiling and Identification of Novel Biomarkers

Michael G. Gravett, MD
Miles J. Novy, MD
Ron G. Rosenfeld, MD
Ashok P. Reddy, PhD
Thomas Jacob, PhD
Mark Turner, MS
Ashley McCormack, PhD
Jodi A. Lapidus, PhD
Jane Hitti, MD
David A. Eschenbach, MD
Charles T. Roberts, Jr, PhD
Srinivasa R. Nagalla, MD

Despite improvements in prenatal care, preterm birth occurs in 11.8% of births in the United States and remains the major obstetrical problem in developed countries.1 Recently, intra-amniotic infection (IAI) has been implicated as a major cause of preterm birth. Intra-amniotic infections cause more than 50% of very low-birthweight neonates born before 30 weeks of gestation and account for the highest number of neonatal deaths, the most serious complications, and a disproportionate share of aggregate perinatal health care costs (estimated in the United States to be $4 billion to $6 billion annually).2,3

Current evidence indicates that if a microorganism causes preterm birth, it usually does so by infection of the chorioamnion and the amniotic fluid or fetus. Infection of the amniotic fluid or the foetal

Context  Intra-amniotic infection (IAI) is commonly associated with preterm birth and adverse neonatal sequelae. Early diagnosis of IAI, however, has been hindered by insensitive or nonspecific tests.

Objective  To identify unique protein signatures in rhesus monkeys with experimental IAI, a proteomics-based analysis of amniotic fluid was used to develop diagnostic biomarkers for subclinical IAI in amniotic fluid and blood of women with preterm labor.

Design, Setting, and Participants  Surface-enhanced laser desorption-ionization/time-of-flight mass spectrometry, gel electrophoresis, and tandem mass spectrometry were used to characterize amniotic fluid peptides in 19 chronically instrumented pregnant rhesus monkeys before and after experimental IAI. Candidate biomarkers were determined by liquid chromatography--tandem mass spectrometry. Polyclonal antibodies were generated from synthetic peptides for validation of biomarkers of IAI. Amniotic fluid peptide profiles identified in experimental IAI were subsequently tested in a cohort of 33 women admitted to Seattle, Wash, hospitals between June 25, 1991, and June 30, 1997, with preterm delivery at 35 weeks or earlier associated with subclinical IAI (n = 11), preterm delivery at 35 weeks or earlier without IAI (n = 11), and preterm contractions with subsequent term delivery at later than 35 weeks (n = 11).

Main Outcome Measures  Identification of peptide biomarkers for occult IAI.

Results  Protein expression profiles in amniotic fluid showed unique signatures of overexpression of polypeptides in the 3- to 5-kDa and 10- to 12-kDa molecular weight ranges in all animals after infection and in no animal prior to infection. In women, the 10- to 12-kDa signature was identified in all 11 patients with subclinical IAI, in 2 of 11 with preterm delivery without IAI, and in 0 of 11 with preterm labor and term delivery without infection (P < .001). Peptide fragment analysis of the diagnostic peak in amniotic fluid identified calgranulin B and a unique fragment of insulinlike growth factor binding protein 1, which were also expressed in maternal serum. Mapping of other amniotic fluid proteins differentially expressed in IAI identified several immunoregulators not previously described in amniotic fluid.

Conclusions  This proteomics-based characterization of the differential expression of amniotic fluid proteins in IAI identified a distinct proteomic profile in an experimental primate chorioamnionitis model that detected subclinical IAI in a human cohort with preterm labor. These diagnostic protein expression signatures, complemented by immunodetection of specific biomarkers in amniotic fluid and in maternal serum, might have application in the early detection of IAI.

JAMA. 2004;292:462-469 www.jama.com

Author Affiliations are listed at the end of this article.

Corresponding Author: Michael G. Gravett, MD, Department of Obstetrics and Gynecology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201 (gravettm@ohsu.edu).
tal membranes (ie, chorioamnionitis) may be acute or chronic depending on specific virulence factors, the microbial inoculum size, and host defense mechanisms; thus, the timing and severity of the clinical presentation vary widely. Most women in preterm labor with intact membranes and a positive amniotic fluid microbial culture are refractory to standard tocolytic therapy and rapidly deliver compared with women in preterm labor with sterile amniotic fluid. Moreover, antibiotic therapy has not prevented preterm delivery in most studies, possibly because the patient subgroup with early IAI that might benefit from antibiotic treatment is identified too late or not at all. Improved diagnostic methods are needed to identify women who may benefit from specific interventions, such as antibiotics or anti-inflammatory agents.

Recent advances in proteomics present a new opportunity to examine the global expression of proteins in tissues and fluids. The proteins or peptides that are preferentially expressed and identified in a disease or pathologic state are well suited for the development of convenient, rapid, sensitive, and specific diagnostic assays. The objective of this study was to discover novel biomarkers for subclinical or occult IAI by proteomic profiling methods. We used surface-enhanced laser desorption-ionization/time-of-flight (SELDI-TOF) mass spectrometry, gel electrophoresis, and tandem mass spectrometry to characterize amniotic fluid peptides in pregnant rhesus monkeys with experimental IAI. The proteome profile that was identified in infected monkeys was then tested for its ability to detect subclinical IAI among women in preterm labor.

METHODS

Experimental IAI in Nonhuman Primates

The protocol was approved by the Institutional Animal Care and Utilization Committee of the Oregon National Primate Research Center and followed humane animal care guidelines. Nineteen pregnant rhesus monkeys (Macaca mulatta) with timed gestations were chronically catheterized and maintained postoperatively, as previously described. Each animal served as its own control for proteomic analysis by serially sampling blood and amniotic fluid before and after infection. Experimental IAI was established between days 126 and 138 of gestation (term is 167 days) by intra-amniotic inoculation of (1) 1×10⁶ colony-forming units (CFU) of group B Streptococcus, type III, suspended in saline (n=7); (2) 1×10⁵ CFU of Ureaplasma parvum (formerly Ureaplasma urealyticum, serovar 1) suspended in 10B media (n=6); or (3) 1×10⁷ to 1×10⁸ CFU of Mycoplasma hominis (n=6) suspended in phosphate-buffered saline with 10% sucrose and 2% endotoxin-free fetal calf serum.

The group B Streptococcus isolate was originally recovered from a neonate with meningitis. The U parvum isolate was from a low-passaged clinical isolate from placenta and membranes of a patient with chorioamnionitis and whose neonate had sepsis. The M hominis isolate was an endometrial isolate from a patient with postpartum endomyometritis. Amniotic fluid samples were collected serially from all animals during the study period for quantitative microbial cultures, white blood cell analysis, cytokine and prostaglandin measurements (as previously reported), and proteomic analysis. Uterine activity was expressed as the hourly contraction area and identified 27% of eligible women and did not differ from nonparticipants in maternal age, race, parity, gravidity, prior preterm delivery, or gestational age at delivery. Informed consent was obtained and the protocol approved by the respective institutional review boards.

Transabdominal amniocentesis was performed and maternal venous blood samples were collected by venipuncture in all study participants at the time of enrollment. Amniotic fluid microbial cultures were performed for facultative and anaerobic bacteria and for genital mycoplasma (M hominis, U parvum), as previously described. Preterm labor was defined as regular uterine contractions at a frequency of 10 minutes or less with either documented cervical change or a cervical dilatation of more than 1 cm or effacement greater than 50%.

Subclinical IAI was defined by a positive amniotic fluid microbial culture and/or an amniotic fluid interleukin 6 (IL-6) concentration greater than 2 ng/mL, histologic evidence for chorioamnionitis (defined as presence of ≥10 polymorphonuclear leukocytes per 400× field in 10 nonadjacent fields and absence of uterine tenderness or fever). We have previously reported that an amniotic fluid IL-6 concentration of more than 2 ng/mL was at or above the 75th percentile for the entire study population and was associated with the detection of bacteria by polymerase chain reaction. Women with cervical dilatation of more than 4 cm or ruptured membranes at admission were excluded.

A subset of patients was identified from this study population for proteomic analysis as reported herein. This subset included 3 groups of 11 patients each. Group 1 included all patients with evidence of subclinical IAI as defined herein for whom amniotic fluid and maternal serum was available; group 2 was a randomly selected subset of patients without documented intrauterine infection but with preterm birth at 35 weeks of gestation or earlier; and group 3 consisted of randomly selected patients without infection and with preterm labor responsive to tocolytic therapy who subsequently delivered near term (>35 weeks).
of gestation). Samples were stored at −20°C until analysis and not thawed more than twice. Repeated thawing did not affect SELDI-TOF profiles or protein identification.

**SELDI-Mass Spectrometry Profiling of Amniotic Fluid**

A total of 0.5 to 3.0 µg of unfraccionated protein from amniotic fluid was analyzed on 3 different protein chip arrays, a normal-phase NP 20 (SiO2 surface), a reverse-phase H4 (hydrophobic surface), and immobilized nickel (IMAC) chips (Ciphergen Biosystems Inc, Fremont, Calif). Chips were incubated for 1 hour with the sample followed by a 5-µL water wash. After drying, a saturated solution of sinapinic acid in 50% acetonitrile (vol/vol) and 0.5% trifluoroacetic acid (vol/vol) was added before reading the arrays on a SELDI-TOF instrument (Ciphergen Protein Biology System II, Ciphergen Biosystems). Spectra were calibrated using internal standards and analyzed using Protein Chip software, version 3.0 (Ciphergen Biosystems).

**Protein Identification by Liquid Chromatography (LC)–Tandem Mass Spectrometry Analysis**

One hundred micrograms of amniotic fluid protein from control and infected samples was reduced with iodoacetamide and resolved on a 15% sodium dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE). The gel was stained with Coomassie blue R-250, and distinct bands from each lane were cut from the gel, destained, and digested in gel with trypsin for 24 hours at 37°C using the method of Courchesne and Patterson. Peptides were then extracted with 0.1% trifluoroacetic acid and purified using Zip-Tip c18 pipette tips from Millipore. After in-gel digestion, samples were analyzed on a Q-Tof-2 mass spectrometer (Micromass, Manchester, England) coupled to a CapLC (Waters Inc, Milford, Mass) and/or on an ion trap (LCQ, ThermoFinnigan, San Jose, Calif) coupled to a 1100 Capillary LC System (Agilent Technologies, Foster City, Calif). Reverse-phase separation was performed using an IntegraFrit C18 75-µm ID × 15-cm fused silica capillary column (Q-TOF2) and Zorbax C-18 0.5-mm × 150-mm microbore column using a 10 µL min⁻¹ flow rate and a gradient of 0% to 40% (75% acetonitrile in water) over 1 hour (LCQ). For Q-Tof-2 analysis, masses of 400 to 1500 Da were scanned for the mass spectrometry survey and masses of 50 to 1900 Da were scanned for tandem mass spectrometry. Tandem mass spectrometry spectra were acquired in an automated mode using standard LCQ software.

**Statistical Analysis**

**Proteomic Analysis.** Analysis of mass spectrometry/mass spectrometry spectra was performed using SEQUEST software, version 3.1 (ThermoFinnigan) and DTASelect (Scripps Research Institute, La Jolla, Calif) as described. Searches were run with the default parameters using a combined, indexed, nonredundant database of protein sequences obtained from the Protein Information Resource and SwissProt (http://www.expasy.org). S-carboxyamidated cysteine was the only considered modification. Spectra from the LCQ mass spectrometer were filtered with a cross-correlation score cutoff of 2.4 for the doubly charged ions. Each spectra and proposed sequence pair selected by DTASelect were visually inspected and the final results were input into a Microsoft Access database (Microsoft, Redmond, Wash).

**Study Population/Outcomes.** The 3 groups of women were compared using 1-way analysis of variance for continuous data (P values from F statistics are presented) and by the Pearson χ² or 2-tailed Fisher exact test for categorical data. For each analysis, overall differences were assessed; no pairwise comparisons were evaluated because of the small sample size. All analyses were performed using SAS, version 8 (SAS Institute Inc, Cary, NC).

Using the Pearson χ² statistic with 2 degrees of freedom and 33 patients allocated equally into the 3 patient groups, the power to detect an effect size of 0.54 was calculated (NCSS and PASS Number Cruncher Statistical Systems, Kaysville, Utah). As an example, an effect of this size corresponds approximately to correctly classifying 9 of 11 in group 1, 7 of 11 in group 2, and 9 of 11 in group 3. Thus, the sample size was adequate to detect effects that would be observed in evaluating currently available diagnostic tests that have sensitivity of 80% and a specificity of 80%.

**Polyclonal Antibodies and Western Immunoblotting**

Immunogenic peptides from corresponding proteins were used to generate rabbit polyclonal antibodies (DSL Laboratories, Webster, Tex). Affinity-purified antibodies were then used for Western blots. One hundred micrograms of amniotic fluid protein was resolved on 4% to 20% SDS-PAGE and transferred to polyvinyl difluoride membranes. From maternal serum, 300 µg of protein was used for immunoprecipitation using insulinlike growth factor binding protein 1 (IGFBP-1) monoclonal antibody (DSL Laboratories) and products underwent Western blot analysis. For detection of calgranulin B in maternal serum, 150 µg of albumin-depleted maternal serum was used for Western blot. The membranes were blocked with 5% fat-free milk in phosphate-buffered saline-tris for 45 minutes at room temperature and incubated with 1 µg/mL of primary antibody (IGFBP-1, azurocidin, vitamin D binding protein from DSL Laboratories, and calgranulin B from Santa Cruz Biotechnology, Santa Cruz, Calif) overnight at 4°C. After 3 washes with TBST tris-buffered saline containing 0.1% (vol/vol) Tween-20, the membrane was incubated with 1G-HRP secondary antibody (Sigma Chemical Co, St Louis, Mo) and visualized with enhanced chemiluminescence.

**RESULTS**

**Experimental IAI in Nonhuman Primates**

Infection was rapidly established following intra-amniotic inoculation. Uterine contractility, which increased from basal levels of 100 mm Hg × s/h to greater than 10000 mm Hg × s/h, oc-
curred at a mean (SD) of 33 (9) hours after inoculation with group B Streptococcus; a mean (SD) of 43 (14) hours after inoculation with U parvum; and a mean (SD) of 62 (14) hours after inoculation with M hominis. Uterine contractions led to progressive cervical dilatation and effacement in all instances. Increases in uterine contractility were preceded by significant elevations in the proinflammatory cytokines tumor necrosis factor α, IL-1β, IL-6, and IL-8 and prostaglandins E2 and F2α, as previously reported.7–9 No animal demonstrated clinical signs of IAI prior to onset of labor. Chorioamnionitis was confirmed histologically in all cases.

**Subclinical Chorioamnionitis in Women**

Demographic and delivery data for the patients are summarized in Table 1. There were no differences in maternal age, race/ethnicity, or parity among the 3 groups. Patients with subclinical IAI had a somewhat earlier gestational age at enrollment and delivered at a significantly earlier gestational age than patients with preterm delivery without infection or those with term delivery. Ninety-one percent of patients with confirmed occult IAI and 75% of those with infection revealed that the 11-kDa peak was first noted as early as 12 hours after inoculation with group B Streptococcus inocula.

Four of 11 patients with occult IAI had microorganisms recovered (2 with Escherichia coli, 1 with Candida albicans, and 1 with mixed anaerobes). Neither U parvum nor M hominis was isolated. The other 7 patients with infection were identified on the basis of markedly elevated amniotic fluid IL-6 concentrations (>2 ng/mL). The mean (SD) amniotic fluid concentration of IL-6 was 27.7 (7.8) ng/mL among these patients compared with 0.68 (0.20) ng/mL among those with preterm delivery without infection and 0.25 (0.13) ng/mL among those with preterm contractions but term delivery (P < .001).

### Identification of Diagnostic Protein Profiles by SELDI-TOF Mass Spectrometry

Whole-spectrum SELDI-TOF mass spectrometry analyses collected at 235 laser intensity of amniotic fluid extracts bound to chemically defined normal-phase chip arrays revealed several peak intensity differences in 3- to 5-kDa and 11- to 12-kDa regions between infected and noninfected primate and human amniotic fluid (Figure 1). The 11-kDa cluster was differentially expressed between control and infected in all cases (P = .004). Longitudinal sampling following group B Streptococcus inoculation revealed that the 11-kDa peak was first noted as early as 12 hours after inoculation and preceded increases in hourly contraction area in infected animals.

As shown in Figure 2, the 11-kDa peak was also detected in experimental IAI induced by the other 2 microbes. In the human cohort, all 11 patients with confirmed occult IAI and none of the 11 patients who subsequently delivered at term had the SELDI-TOF mass spectrometry profile consistent with IAI and characterized by the presence of the 11-kDa peak. This profile was also present in 2 of 11 patients in whom infection was not confirmed but who delivered prematurely (Table 1). These differences in the proteome profile could not be attributed to differences in gestational age.

### Global Analysis of Amniotic Fluid Proteins in IAI Using LC-Tandem Mass Spectrometry

Global analysis of primate and human infected and noninfected amniotic fluid using 1-dimensional gel electrophoresis separation and in-gel digestion of specific bands identified expression of various immunoregulatory proteins not described previously in IAI (Table 2). Liquid chromatography–tandem mass spectrometry analysis of the approximately 11-kDa band from 1-dimensional gel identified several polypeptides derived from calgranulins and a unique fragment of IGFBP-1.

### Immunodetection of IAI Biomarkers

To validate the differential expression of proteins identified in IAI, we selected 2 markers identified from the 11-kDa SELDI-TOF mass spectrometry profile (calgranulin B and IGFBP-1), 1 immunoregulatory molecule (azurocidin), and an unregulated protein (vitamin D bind-

### Table 1. Identification of Subclinical Intra-amniotic Infection in Humans Using Surface-Enhanced Laser Desorption-Ionization-Time-of-Flight Mass Spectrometry Profiling

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Preterm Delivery (≤ 35 wk)</th>
<th>Term Delivery (&gt; 35 wk)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intra-amniotic Infection</td>
<td>No Intra-amniotic Infection</td>
<td>After Preterm Labor</td>
</tr>
<tr>
<td>Maternal age, y</td>
<td>(n = 11)</td>
<td>(n = 11)</td>
<td>(n = 11)</td>
</tr>
<tr>
<td></td>
<td>24.5 (5.4)</td>
<td>26.6 (9.0)</td>
<td>25.6 (6.0)</td>
</tr>
<tr>
<td>White race, No. (%)</td>
<td>6 (55)</td>
<td>4 (36)</td>
<td>6 (55)</td>
</tr>
<tr>
<td>Parity</td>
<td>1.9 (1.6)</td>
<td>1.9 (1.5)</td>
<td>3.0 (2.5)</td>
</tr>
<tr>
<td>Gestational age, wk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrollment</td>
<td>26.9 (1.1)</td>
<td>28.6 (1.1)</td>
<td>30.3 (1.1)</td>
</tr>
<tr>
<td>Delivery</td>
<td>27.3 (0.9)</td>
<td>29.8 (1.0)</td>
<td>37.0 (0.9)</td>
</tr>
<tr>
<td>Time from enrollment to delivery, d</td>
<td>2.1 (5.6)</td>
<td>8.4 (6.3)</td>
<td>46.9 (5.6)</td>
</tr>
<tr>
<td>Diagnostic protein profile, No./total No. (%)</td>
<td>11/11 (100)</td>
<td>2/11 (18)</td>
<td>0</td>
</tr>
</tbody>
</table>

*Values are expressed as mean (SD) unless otherwise indicated.
†One-way analysis of variance.
‡Pearson χ² test.
§Fisher exact test.

©2004 American Medical Association. All rights reserved.
ing protein) identified in global protein expression analysis. As shown in Figure 3, Western blot analysis confirmed all 3 biomarkers showing differential expression, consistent with the protein identification experiments performed on IAI amniotic fluid.

Using specific antibodies developed against IGFBP-1 and calgranulin B, we investigated whether differentially expressed proteins in amniotic fluid could be identified in pooled maternal serum from a limited number of patients (n=5) for whom serum samples were available. In this limited analysis, the 11-kDa proteolytic fragment of IGFBP-1 and of calgranulin B, corresponding to the 11-kDa peak that was differentially present in infected vs control amniotic fluid, was also detected in maternal serum in response to IAI (Figure 3B) and in nonhuman primates following experimental IAI (data not shown). Azurocidin was not detected in serum.

**COMMENT**
Intra-amniotic infection is an important and potentially preventable cause of premature births, neonatal sepsis, periventricular leukomalacia/cerebral palsy, and maternal febrile morbidity.2,3,19-21 Overt or subclinical IAI is present in at least 50% of extremely premature births; an inverse relationship has been demonstrated between gestational age at birth and both the frequency of microorganisms recovered from the chorioamnion and histologic chorioamnionitis.22,11

Despite growing evidence that IAI is responsible for a substantial proportion of premature births in the United States, there is a lack of validated serologic assays for its detection.
States, antibiotic treatment has had limited success in treating patients with preterm labor and intact fetal membranes or in preventing preterm delivery.3,5 This dilemma may be attributable in part to misclassification and patient selection bias, whereby the subpopulation of women with occult IAI and intact fetal membranes that might benefit from antibiotics is not reliably distinguished from women without infection. Accurate and early diagnosis of IAI would facilitate early and appropriate interventions as well as enhance the design of therapeutic trials.

Early diagnosis of IAI is problematic, however, because clinical signs and symptoms (including preterm labor) tend to be late manifestations of this condition. Furthermore, the available noninvasive diagnostic tests have limited predictive value, or, as in the case of measurement of IL-6, polymerase chain reaction tests, or microbial cultures, the results are often delayed and amniocentesis is required.12,22 We previously demonstrated in a nonhuman primate model the causal relationship between IAI with group B Streptococcus, *U* parvum, or *M* hominis and preterm labor, which resembles the clinical progression of events that is observed in women with IAI.7,9 These microorganisms are also frequently isolated from the amniotic fluid and chorioamnion in women with preterm labor and delivery.11,23,24 In the rhesus monkey, as in women, histologic appearance of the fetal membranes is consistent with subacute chorioamnionitis.

Therefore, we used this experimental model to search for novel amniotic fluid protein and peptide biomarkers for IAI with the expectation that they could similarly be found in human amniotic fluid and would provide the basis for the subsequent development of sensitive and specific assays to detect subclinical IAI. We identified a unique amniotic fluid peptide profile in IAI by SELDI-TOF that appeared within 12 hours after intraamniotic inoculation of microorganisms and was reliably present before the onset of labor or other clinical signs or symptoms of infection. We validated our observations in a cohort of women in preterm labor by microbiologic, biochemical, or histologic evidence of chorioamnionitis and in a control group without evidence of infection.

We used 2 distinct proteomic approaches: a low-resolution rapid protein fingerprinting approach (SELDI-TOF mass spectrometry) that generates distinct expression profiles and is amenable to developing rapid screening assays, together with a high-throughput protein identification approach (LC–tandem mass spectrometry) that provides the identity of the biomarkers suitable for identification by conventional immunoassays.

The detection of a differentially expressed 11-kDa peak in SELDI-TOF mass spectrometry in the setting of IAI in the experimental primate model, which used clinically relevant microor-

---

**Figure 2. Detection of Intra-amniotic Infection Resulting From Different Microorganisms**

<table>
<thead>
<tr>
<th>GenBank Account No.</th>
<th>Protein ID</th>
<th>Protein Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>U12026</td>
<td>CAPG_HUMAN</td>
<td>Macrophage capping protein*</td>
</tr>
<tr>
<td>X83006</td>
<td>NGAI_HUMAN</td>
<td>Neutrophil gelatinase-associated lipocalin*</td>
</tr>
<tr>
<td>M19507</td>
<td>PERM_HUMAN</td>
<td>Myeloperoxidase precursor*</td>
</tr>
<tr>
<td>M22200</td>
<td>PLSL_HUMAN</td>
<td>L-plastin (lymphocyte cytosolic protein 1)</td>
</tr>
<tr>
<td>NM001700</td>
<td>AZU1_HUMAN</td>
<td>Azurocidin†</td>
</tr>
<tr>
<td>Z38026</td>
<td>FA39_HUMAN</td>
<td>Antibacterial protein FALL-39 precursor*</td>
</tr>
<tr>
<td>AF159456</td>
<td>Q9UKJ4</td>
<td>Gp-340 variant protein</td>
</tr>
<tr>
<td>AL355392</td>
<td>Q9H4V6</td>
<td>Novel protein similar to mouse von Ebner salivary gland protein, isoform 2</td>
</tr>
<tr>
<td>M93056</td>
<td>ILEU_HUMAN</td>
<td>Leukocyte elastase inhibitor*</td>
</tr>
<tr>
<td>Y00279</td>
<td>S105_HUMAN</td>
<td>Calgranulin A</td>
</tr>
<tr>
<td>X06233</td>
<td>S109_HUMAN</td>
<td>Calgranulin B*†</td>
</tr>
</tbody>
</table>

*Peptides representing these proteins are more abundantly or uniquely detected in infected amniotic fluid.†Proteins also shown to be differentially expressed by immunoassays.
gonisms and in women infected with different microorganisms, confirms this signature for IAI caused by a broad range of pathogens. Peptides within the differentially expressed peak may represent a basic intrauterine immune response to infection since one set of proteins identified in this unique cluster, ie, the calgranulins, are members of the S-100 calcium-binding protein family, expressed by macrophages and by epithelial cells in acutely inflamed tissues. The second candidate from this cluster, a specific proteolytic fragment of IGFBP-1, indicates a potential protease-related mechanism in response to infection. Intrauterine immune responses. Antibacterial proteins Fall-39 and azurocidin in amniotic fluid in response to infection provides new insights into intrauterine immune responses. Antibacterial protein Fall-39 (LL-37) binds to bacterial lipopolysaccharides, is a potent chemotactic factor for mast cells, and serves as a first-line defense to prevent local infection and systemic invasion of microbes. Azurocidin (CAP37) is a cationic antimicrobial protein isolated from human neutrophils with important implications in host defense and inflammation. Glycoprotein-340 variant protein is a scavenger receptor previously identified in lung that binds to bacteria. Identification of these proteins complements the sensitive proteomic approaches used to identify biomarkers for IAI. Since our experimental objectives were focused on the discovery of novel biomarkers unique to IAI, we did not look for the peptide profiles of cytokines such as IL-6.

In addition to the above immunomodulators, the detection of antibacterial proteins Fall-39 and azurocidin in amniotic fluid in response to infection provides new insights into intrauterine immune responses. Antibacterial protein Fall-39 (LL-37) binds to bacterial lipopolysaccharides, is a potent chemotactic factor for mast cells, and serves as a first-line defense to prevent local infection and systemic invasion of microbes. Azurocidin (CAP37) is a cationic antimicrobial protein isolated from human neutrophils with important implications in host defense and inflammation. Glycoprotein-340 variant protein is a scavenger receptor previously identified in lung that binds to bacteria. Identification of these proteins complements the sensitive proteomic approaches used to identify biomarkers for IAI. Since our experimental objectives were focused on the discovery of novel biomarkers unique to IAI, we did not look for the peptide profiles of cytokines such as IL-6.

Currently available laboratory tests used to confirm the diagnosis of IAI include measurement of maternal C-reactive protein, direct examination of amniotic fluid for leukocytes or bacteria on Gram stain, amniotic fluid microbiological culture or polymerase chain reaction, measurement of amniotic fluid glucose and IL-6 concentrations, and detection of amniotic fluid leukocyte esterase. Only microbial cultures and broad-spectrum bacterial recombinant DNA polymerase chain reaction of amniotic fluid appears to be sensitive and specific for IAI. However, microbial cultures for genital mycoplasmas or polymerase chain reaction–based tests are not widely available and amniocentesis is required to obtain amniotic fluid.

One advantage of a proteomics-based approach is that candidate peptide biomarkers lend themselves to the development of rapid point-of-service and cost-effective diagnostic immunoassays that can be completed within hours. By analogy with other amniotic fluid and serum screening tests (eg, a-fetoprotein for neural tube defects), we predicted that peptides identified within infected amniotic fluid could also be detected in maternal serum and might lead to the development of noninvasive diagnostic tests. Our preliminary results using pooled maternal serum samples suggest the feasibility of this approach, in that IGFBP-1–restrictive fragment and calgranulin B are 2 such candidate biomarkers that appear in both amniotic fluid and maternal blood during IAI but not in the absence of infection (Figure 3B). In contrast, elevated IL-6 concentrations have not been reported in maternal serum in association with intra-amniotic infection.

In summary, we used a proteomics-based analysis of amniotic fluid to identify biomarkers for IAI in both an experimental nonhuman primate model and a cohort of women with preterm labor and occult IAI. Diagnostic protein expression profiles were identified by...
SELDI-TOF mass spectrometry profiling that was both sensitive and specific in detecting IAI. High-throughput analysis of expressed proteins in amniotic fluid identified expression of several immunoregulatory molecules for the first time. Immunodetection of proteins detected in the diagnostic 11-kDa peak (IGFBP-1 and calgranulin B) confirmed the presence and differential expression of these biomarkers in amniotic fluid and in maternal blood during IAI.

Our findings hold promise for the future development of rapid and noninvasive assays to detect occult IAI during pregnancy. This would be an important breakthrough since it would allow clinicians and investigators to target a particular subgroup of women at high risk of premature delivery for specific interventions and in therapeutic trials. Finally, these studies demonstrate the potential utility of proteomics-based approaches to identify specific biomarkers and diagnostic profiles for infectious and inflammatory processes and in pathophysiologic conditions of pregnancy.

Author Affiliations: Division of Reproductive Sciences, Oregon National Primate Research Center, Beaverton, Ore (Dr Gravett and Novy); Departments of Obstetrics and Gynecology (Dr Gravett) and Pediatrics (Drs Rosenfeld, Roberts, and Nagalla) and Division of Biostatistics, Public Health and Preventive Medicine (Dr Lapidus), Oregon Health and Science University, and ProteoGenix Inc (Drs Reddy, Jacob, and McCormack and Mr Turner), Portland, Ore; Lucile Packard Foundation for Children’s Health, Palo Alto, Calif (Dr Rosenfeld); Department of Obstetrics and Gynecology, University of Washington (Drs Hitti and Eschenbach), Seattle, Wash.

Author Contributions: Dr Gravett had full and complete access to all of the data in the study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Gravett, Rosenfeld, Eschenbach, Nagalla.

Acquisition of data: Gravett, Rosenfeld, Reddy, Jacob, Turner, McCormack, Hitti, Eschenbach, Roberts, Nagalla.

Analysis and interpretation of data: Gravett, Novy, Rosenfeld, Reddy, Jacob, Lapidus, Hitti, Eschenbach, Roberts, Nagalla.

Drafting of manuscript: Gravett, Novy, Rosenfeld, Hitti, Eschenbach, Nagalla.

Critical revision of the manuscript for important intellectual content: Gravett, Novy, Rosenfeld, Reddy, Jacob, Turner, McCormack, Lapidus, Hitti, Eschenbach, Roberts.

Statistical analysis: Gravett, Lapidus, Hitti.

Obtained funding: Gravett, Novy, Eschenbach, Nagalla.

Administrative, technical, or material support: Gravett, Rosenfeld, Reddy, Jacob, Turner, McCormack, Eschenbach, Roberts.

Study supervision: Gravett, Novy, Rosenfeld, Eschenbach, Nagalla.

Funding/Support: This study was supported by National Institutes of Health grants AI42490, HD065199, RR00163, and 1U24DK5870, by grant F99-285 from the March of Dimes Birth Defects Foundation, and by ProteoGenix Inc.

Role of the Sponsors: The sponsors played no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

Acknowledgment: We gratefully acknowledge the expert assistance provided by Jing Huang, PhD, for technical assistance and by Lynn B. Duffy, MT, Gal H. Cassell, PhD, and staff at the Diagnostic Mycoplasma Laboratory, Birmingham, Ala, in the preparation and culture of mycoplasmas.

REFERENCES


©2004 American Medical Association. All rights reserved.
Marco Caruso, MD  
Enrico Hoffmann, MD  
Department of Internal Medicine  
Cardiovascular and Nephro-Urological Diseases  
University of Palermo  
Claudio Franceschi, MD  
Italian National Research Center on Aging  
Ancona, Italy  
Department of Experimental Pathology and Interdepartmental Center “L. Galvani”  
University of Bologna  
Bologna, Italy  
Calogero Caruso, MD  
marcco@unipa.it  
Immunosenescence Unit  
Department of Pathobiology and Biomedical Methodologies  
University of Palermo

Access to Data: Dr C. Caruso had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analyses.

Funding/Support: This study was supported by grants from the University of Palermo (Drs Candore, Lio, Colonna-Romano, and C. Caruso) and from the University of Bologna (Dr Franceschi), as well as funds from the EU 5FP T-CIA project (Dr Franceschi) and the Italian Ministry of Health (Genetic and Non-genetic Factors of Health in Elderly) (Drs Franceschi and Colonna-Romano). The collaboration between the “Gruppo di Studio sull’Immunosenescenza” coordinated by Dr C. Caruso and the Istituto Nazionale di Riposo e Cura per Anziani (INRCA), Ancona, was supported by an INRCA grant (Longevity and Elderly Disability Biological Markers).

Role of the Sponsors: The organizations funding this study had no role in the design and conduct of the study; the collection, interpretation, and analysis of the data; the preparation of the data; or the preparation, review, or approval of the manuscript.

Disclaimer: Dr Balistreri is a PhD student in the pathobiology PhD curriculum (directed by Dr C. Caruso) of Palermo University and this work is in partial fulfillment of the requirement for the PhD.


